0
0
Researchers have identified the gene Asah1 as a crucial factor in preventing the progression of nonalcoholic fatty liver disease (NAFLD) to more severe forms of liver disease. This discovery offers potential new therapeutic strategies for NAFLD patients.
NAFLD is a prevalent condition affecting approximately 25% of the global population, with about 25% of these individuals progressing to nonalcoholic steatohepatitis (NASH), a more severe form that can lead to cirrhosis or liver cancer. The liver’s role in processing fats and nutrients makes it susceptible to fat accumulation, especially with poor dietary choices and lack of exercise.
The study, published in The American Journal of Pathology, highlights the importance of lysosomal function in liver cells. Impaired lysosomal activity leads to lipid accumulation, exacerbating NAFLD. By analyzing gene-profiling data from obese patients, researchers found that Asah1 expression was positively correlated with NAFLD stages.
Yang Zhang, Ph.D., from the University of Houston’s College of Pharmacy, noted that understanding the role of Asah1 could inform new treatments for NAFLD and NASH, addressing the limited current options available.
Disclaimer: This article is based on research findings and should not be considered medical advice. Consult healthcare professionals for concerns regarding liver health or NAFLD.
